MAGNOLIA is a multicenter study investigating the effect of abelacimab compared to dalteparin on venous thromboembolism or bleeding in patients with gastrointestinal or urogenital cancers.
Aim of the study
The study investigates whether abelacimab is non-inferior to dalteparin in preventing thromboembolism recurrence in patients with gastrointestinal/urogenital tumor disease and recent venous thromboembolism. A period of 6 months after study inclusion is examined.
Who can take part?
Adult patients with gastrointestinal/urogenital cancer that cannot be resected surgically, who have suffered an acute venous thromboembolism and require blood thinning with low-molecular-weight heparin.
Procedure
After inclusion in the study, randomization takes place in a 1:1 ratio into a study arm with blood thinning using abelacimab and a study arm with blood thinning using heparin. The duration of therapy is 6 months. During this period, it will be investigated whether the key study endpoints occur (thromboembolism recurrence, bleeding). The examination of the study endpoints is blinded.
Compensation
Original study name
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE
BASEC number
2022-00896
Financial support from